Daryl Jun Kai Chin

Daryl Jun Kai Chin

Auto-generated profile, based on publicly available information

Daryl Jun Kai Chin

Singapore Immunology Network, Agency for Science, Technology and Research, Singapore 138648, Singapore

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JBJuliane L. Buhl
Juliane L. Buhl
JKJannet Koelewijn
Jannet Koelewijn
SMStijn De Munter
Stijn De Munter
VCVictoria M. Cruz
Victoria M. Cruz
DCDaryl Jun Kai Chin
Daryl Jun Kai Chin
CJClaudia Yvonne Janda
Claudia Yvonne Janda
Malignant rhabdoid tumors are highly aggressive pediatric malignancies with limited treatment options and poor outcomes. To expand therapeutic options, we employed mass spectrometry-based cell surface proteomics on malignant rhabdoid tumor and patient-matched normal kidney organoids to identify potential CAR T cell targets. Integrating these findings with transcriptomics and protein expression data, we revealed ROBO1 as a promising target, showing strong and uniform expression across malignant rhabdoid and other pediatric tumors. ROBO1-targeted CAR T cells displayed potent anti-tumor activity in vitro , effectively eliminating tumor cells in co-cultures with organoids from malignant rhabdoid tumors, rhabdomyosarcoma, and neuroblastoma. In vivo, ROBO1 CAR T cells infiltrated tumors, induced potent tumor regression and significantly increased survival in malignant rhabdoid tumor-bearing mice. These findings establish ROBO1 as a compelling therapeutic target for CAR T cell therapy and offer a promising approach to address the critical need for effective treatments in high-risk pediatric solid tumors. Statement of significance: This study identifies ROBO1 as a promising CAR T cell target for pediatric solid tumors. Using patient-derived tumor organoids and tissues, we demonstrate strong ROBO1 expression across several tumor entities and robust anti-tumor efficacy of ROBO1-targeted CAR T cells in vitro and in vivo , underscoring its potential for clinical translation.